RegeneRx Biopharmaceuticals, Inc. RGRX today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for its application claiming methods for treating, preventing, inhibiting or reducing tissue deterioration due to congestive heart failure disease using Thymosin beta 4, its isoforms and fragments, and important analogs. The patent is projected to expire July 2027.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
